Value Sense
SLN
Silence Therapeutics plc (SLN)
Last Price$4.3(4.0%)
Market Cap$211.4B
Intrinsic value score
N/A
Great
Intrinsic value
N/A
DCF value - N/A Relative value - N/A
Undervalued
N/A
LTM P/E
N/A
Peer set median (28.8x)
Discount rate
N/A
SLN
is 99.8% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

SLN Intrinsic value

Key Highlights:
Relative Value vs Current Share Price
As of Mar 03, 2025 SLN Relative Value is $0.0, which is overvalued by 99.7%, compared to current share price of $4.3.
DCF Value vs Current Share Price
As of Mar 03, 2025 SLN DCF Value is N/A, which is undervalued by N/A, compared to current share price of $4.3.
Methodology
Price per share, $
SLN
Intrinsic value$0.0
Overvalued by99.8%
Current share price
4.3
Relative value
0.0
DCF value
not available

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

SLN Historical Intrinsic Value

Crunching data... Almost there!

SLN vs Peer Set: Intrinsic Value Comparison

General

Intrinsic Value

Financials

Company name

Undervaluation/Overvaluation

Revenue growth

EPS growth

Net income margin

Silence Therapeutics plc logo
Silence Therapeutics plcSLN
(99.8%)
45.7%
(6.7%)
(170.5%)
Median Peer Set
18.9%
(47.6%)
0.4%
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
(97.4%)
N/A
(68.7%)
N/A
argenx SE logo
argenx SEARGX
(82.5%)
198.6%
(60.5%)
(24.1%)
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
(61.6%)
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
(59.6%)
11.7%
N/A
(4.9%)
Incyte Corporation logo
Incyte CorporationINCY
(33.6%)
14.8%
(94.0%)
0.8%
Novo Nordisk A/S logo
Novo Nordisk A/SNVO
(32.9%)
24.9%
142.8%
34.8%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
37.8%
23.6%
25.7%
41.5%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
48.0%
8.3%
10.4%
31.1%
BioNTech SE logo
BioNTech SEBNTX
48.6%
(77.4%)
(89.7%)
24.4%
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
1,137.3%
73.7%
(56.5%)
(35.9%)

Explore more intrinsic value tools hub for SLN

Peter Lynch Fair Value
Intrinsic Value
Earnings Power Value
Ben Graham Fair Value
Earnings growth model
DCF value calculator
Discount rate
Peter Lynch charts
Reverse DCF
Relative Value

FAQ

What is Silence Therapeutics plc intrinsic value?

As of Mar 03, 2025, Silence Therapeutics plc Intrinsic Value is $0.0. This suggests it may be overvalued by 99.8% compared to its current price of around $4.3.

What is Silence Therapeutics plc DCF (discounted cash flow) valuation?

As of Mar 03, 2025, Silence Therapeutics plc's Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by N/A to its current price of around $4.3, using a discount rate of N/A and terminal growth rate of 3.0%.

Is Silence Therapeutics plc overvalued or undervalued?

Silence Therapeutics plc is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $0.0, compared to a market price of around $4.3. This suggests a potential overvaluation of 99.8%.